MedTrace Logo

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

NCT05394493 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2023-12-06

No results posted yet for this study

Summary

An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.

Conditions

  • Advanced Renal Cell Carcinoma

Interventions

DRUG

avelumab

as provided in real world setting

DRUG

axitinib

as provided in real world settings

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-11
Primary Completion
2023-08-30
Completion
2023-08-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05394493 on ClinicalTrials.gov